NFKB1 and metabolic dysfunction-associated steatohepatitis: NASH patients are characterized by increased phosphorylation (i.e., activation) of JNK [23,36,37], which can be due both to a direct effect of FFAs, or to the activation of nuclear factor-κB (NF-κB) pathway [26,38].